Riskpilot← Back to searchSign inGet full accessSpixia Biotechnology AB
ABActiveOrg 5560382961Gammelhyttan Domargården 125Research and experimental development on natural sciences and engineering · NACE 7210Est. 19390 employees
Revenue 2025
SEK 0
EBITDA margin
—
-755% vs 2024
Equity ratio
75.7%
Financial strength
Net profit 2025
SEK -175K
-249% vs 2024
| Revenue | SEK 0 | — |
| EBITDA | SEK -168K | -755% |
| Net profit | SEK -175K | -249% |
| Total assets | SEK 180K | +71% |
| Equity | SEK 136K | +121% |
| Employees | 0 | — |
Legal name
Spixia Biotechnology AB
Org number
5560382961
Legal form
Aktiebolag
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
28 april 1939
Share capital
SEK 102 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2025-04-30
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Dessutom har verkställande direktören rätt att teckna firman beträffande löpande förvaltningsåtgärder
Company purpose
Föremålet för bolagets verksamhet är att bedriva verksamhet inom forskning och bioteknologi såsom att äga andra bioteknologiföretag och att äga immaterialrättstillgångar, bedriva konsultverksamhet inom bioteknologi, utveckla, äga och sälja innovationer, köpa, sälja och producera biotekniska produkter, köpa, sälja och hyra ut bioteknisk utrustning, förvalta värdepapper och fastigheter samt därmed förenlig verksamhet.
Address
Gammelhyttan Domargården 125
Email
spixia.strid@proton.me
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 90 | 0 | −0 | 0 |
| Staff expenses | — | — | — | — | — |
| EBITDA | −40 | 66 | −20 | −20 | −168 |
| Depreciation & amort. | −58 | −58 | −58 | −31 | −7 |
| EBIT | −98 | 7 | −78 | −50 | −175 |
| Net financials | — | — | 0 | 0 | 0 |
| Profit before tax | −98 | 7 | −78 | −50 | −175 |
| Tax | −0 | −2 | — | — | — |
| Net profit | −98 | 6 | −78 | −50 | −175 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 225 | 234 | 155 | 105 | 180 |
| Equity | 184 | 190 | 112 | 62 | 136 |
| Long-term debt | 0 | — | — | — | — |
| Short-term debt | 42 | 44 | 44 | 44 | 44 |
| Total debt | 42 | 44 | 44 | 44 | 44 |
EBITDA margin
-16815600.0%
This company
15.8%
Market median
-106427948% vs market
20212025
Equity ratio
75.7%
This company
38.2%
Market median
+98% vs market
20212025
Return on equity
-128.8%
This company
18.4%
Market median
-800% vs market
20212025
Net profit margin
-17532000.0%
This company
8.1%
Market median
-216444544% vs market
20212025
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20212025
Debt / equity
0.32×
This company
0.62×
Market median
+48% vs market
20212025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2024-05-01 – 2025-04-30
- Annual report 2024Filed via Bolagsverket / SCB · Period 2023-05-01 – 2024-04-30
- Annual report 2023Filed via Bolagsverket / SCB · Period 2022-05-01 – 2023-04-30
- Annual report 2022Filed via Bolagsverket / SCB · Period 2021-05-01 – 2022-04-30
- Annual report 2021Filed via Bolagsverket / SCB · Period 2020-05-01 – 2021-04-30
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
KÅ Chief Executive Officer | Chief Executive Officer | 2022 |
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Chairman | 2022 | |
| Deputy Board Member | 2025 | |
| Former (1) | ||
| Deputy Board Member | 2022 – 2025 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Spixia Biotechnology AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Karl Åke Strid | Chief Executive Officer | 0 companies |
| Erik Sören Andersson | Chairman | 0 companies |
| Per Staffan Söljén | Deputy Board Member | 0 companies |
| Per Mattias Jonsson | Deputy Board Member | 0 companies |